Global End Stage Renal Disease Market to 2027 – by Treatment, Diagnosis, End-User and Region –

Global End Stage Renal Disease Market to 2027 – by Treatment, Diagnosis, End-User and Region –

Global End Stage Renal Disease Market to 2027 – by Treatment, Diagnosis, End-User and Region –

DUBLIN–(BUSINESS WIRE)–The “End Stage Renal Disease Market Research Report by Treatment, by Diagnosis, by End-User, by Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to’s offering.

The Global End Stage Renal Disease Market size was estimated at USD 30.85 billion in 2020, is expected to reach USD 35.25 billion in 2021, and is projected to grow at a CAGR of 14.63% to reach USD 80.27 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the End Stage Renal Disease Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global End Stage Renal Disease Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global End Stage Renal Disease Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global End Stage Renal Disease Market?

4. What is the competitive strategic window for opportunities in the Global End Stage Renal Disease Market?

5. What are the technology trends and regulatory frameworks in the Global End Stage Renal Disease Market?

6. What is the market share of the leading vendors in the Global End Stage Renal Disease Market?

7. What modes and strategic moves are considered suitable for entering the Global End Stage Renal Disease Market?

Market Dynamics


  • Proliferation in the number of people suffering from chronic kidney disease
  • Growing geriatric population with hypertension and diabetes
  • Increasing lifestyle changes including smoking, drinking, and consumption of processed food


  • Risk of complications
  • Stringent regulatory policies for dialysis products


  • Rising introduction of new technologically enhanced products such as wearable artificial kidney
  • Increasing research and development investment coupled with collaborations among manufacturers


  • Stringent regulatory protocols for the approval of new devices

Companies Mentioned

  • Abbott
  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • BD
  • Bristol-Myers Squibb Company
  • Cantel Medical
  • Davita Healthcare Partners Inc.
  • F. Hoffmann-La Roche Ltd
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline PLC
  • JMS Co. Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd
  • Medtronic
  • Nikkiso Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900